Standard Report | Premium Report | |
---|---|---|
Current State of the Industry | ![]() |
![]() |
Market Size (industry trends) | ![]() |
![]() |
Market Forecast (5-year projection) | ![]() |
|
Products/Services Breakdown | ![]() |
|
Revenue per State | ![]() |
![]() |
Financial Metrics | ![]() |
![]() |
Salary & Compensation Statistics | ![]() |
![]() |
Public Company Information | ![]() |
![]() |
Key Private Companies | ![]() |
|
Government Vendors | ![]() |
|
Instant Download - Available immediately upon purchase | ![]() |
![]() |
Download both PDF and Excel
![]() ![]() |
![]() |
![]() |
Download now: |


2021 U.S. Industry Statistics & Market Research - Research & Development in the Physical, Engineering & Life Sciences
Market Size & Industry Statistics
The total U.S. industry market size for Research & Development in the Physical, Engineering & Life Sciences:
Industry statistics cover all companies in the United States, both public and private, ranging in size from small businesses to market leaders.
In addition to revenue, the industry market analysis shows information on employees, companies, and average firm size.
Investors, banks, and business executives use growth rates and industry trends to understand the market outlook and opportunity.

Statistics | 2014 2015 2016 2017 2018 2019 2020 | |
---|---|---|
Market Size (Total Sales/Revenue) |
Order at top of page | |
Total Firms | ||
Total Employees | ||
Average Revenue Per Firm | ||
Average Employees Per Firm | ||
Average Revenue Per Employee |
Market Forecast
Market forecasts show the long term industry outlook and future growth trends. The following extended five-year / six-year demand forecast projects both short-term and long-term trends.
Forecast / Industry Outlook | 2021 | 2022 | 2023 | 2024 | 2025 | |
---|---|---|---|---|---|---|
Market Forecast ($ millions) | ||||||
Projected Industry Growth Rate (%) |
Product & Services Breakdown
Research products and services in the Research & Development in the Physical, Engineering & Life Sciences industry generating sales. Note that products are broken into categories with different levels of classification.Product Description | Number of Companies | Sales ($ millions) | Percent of Total Sales |
---|---|---|---|
Industry Total |
|||
Basic And Applied Research In The Physical And Engineering Sciences |
|||
Basic And Applied Research In - Chemistry And Chemical Engineering |
|||
Basic And Applied Research In - Computer, Electrical, And Electronic Engineering |
|||
Basic And Applied Research In - Earth And Environmental Sciences |
|||
Basic And Applied Research In - Material, Mechanical, And Industrial Engineering |
|||
Basic And Applied Research In - Physics |
|||
Basic And Applied Research In - Astronomy |
|||
Basic And Applied Research In - Other Physical Sciences, Including Math, And Other Natural And Exact Sciences (Exclude Biologica |
|||
Basic And Applied Research In - Other Engineering Sciences, Including Civil, Construction, And Other Engineering |
|||
Computer Systems Design, Development, And Integration Services |
|||
Testing Services (Physical Or Product), Excluding Medical And Veterinary Services |
|||
Basic And Applied Research In Biotechnology |
|||
Basic And Applied Research In The Life Sciences (Exclude Biotechnology.) |
|||
Basic And Applied Research In - Pharmacology And Pharmaceutical Sciences |
|||
Basic And Applied Research In - Medical And Health Sciences |
|||
Basic And Applied Research In - Biological Science |
|||
Basic And Applied Research In - Agriculture, Forestry, And Allied Sciences |
|||
Basic And Applied Research In - Animal Production, Fisheries, And Veterinary Sciences |
|||
Basic And Applied Research In - Other Life Sciences, Excluding Biotechnology |
|||
Basic And Applied Research In The Social Sciences And Humanities |
|||
Basic And Applied Research In - Education |
|||
Development Services For Goods |
|||
Development Services For Service Products Processes, Systems, Or Methods |
|||
Outright Sale Of Original Works Of Intellectual Property |
|||
Advisory And Consulting Services For Research And Development Activities |
|||
Engineering Services |
|||
Licensing Of Rights To Use Intellectual Property |
|||
Licensing Of Rights To Use Intellectual Property Protected By Copyright |
|||
Licensing Of Rights To Use Intellectual Property Protected As Industrial Property |
|||
Resale Of Merchandise |
|||
All Other Receipts |
|||
All Other Operating Receipts |
|||
Contributions, Gifts, And Grants - Government |
|||
Contributions, Gifts, And Grants - Private |
|||
Investment Income, Including Interest And Dividends |
|||
All Other Revenue |
U.S. Geographic Distribution: Revenue Statistics by State
Market Size by State ($ millions) indicates how the industry's competition is distributed throughout the country. State-level information can identify areas with higher and lower industry market share than average.
Income Statement (Average Financial Metrics)
Financial metrics provide a snapshot view of a benchmark "average" company. Key business metrics show revenue and operating costs. The data collected covers both public and private companies.Industry Average | Percent of Sales (Industry Benchmark) | |
---|---|---|
Total Revenue | Order at top of page |
|
Operating Revenue | ||
Cost of Goods Sold | ||
Gross Profit | ||
Operating Expenses | ||
Pension, profit sharing plans, stock, annuity | ||
Repairs | ||
Rent paid on business property | ||
Charitable Contributions | ||
Depletion | ||
Domestic production activities deduction | ||
Advertising | ||
Compensation of officers | ||
Salaries and wages | ||
Employee benefit programs | ||
Taxes and Licenses | ||
Bad Debts | ||
Depreciation | ||
Amortization | ||
Other Operating Expenses | ||
Total Operating Expenses | ||
Operating Income | ||
Non-Operating Income | ||
EBIT (Earnings Before Interest and Taxes) | ||
Interest Expense | ||
Earnings Before Taxes | ||
Income Tax | ||
Net Profit Net Income | ||
Financial Ratio Analysis
Financial ratio information can be used to benchmark how a Research & Development in the Physical, Engineering & Life Sciences company compares to its peers. Accounting statistics are calculated from the industry-average for income statements and balance sheets.Profitability & Valuation Ratios | Industry Average |
---|---|
Company valuation can be measured based on the firm's own performance, as well as in comparison against its industry competitors. These metrics show how the average company in the Research & Development in the Physical, Engineering & Life Sciences industry is performing. | |
Profit Margin Gross Profit Margin, Operating Profit Margin, and Net Profit Margin. Show company earnings relative to revenues. |
|
Return on Equity (ROE) Return on Equity (ROE) is net income as a percentage of shareholders' equity. Shareholders' Equity is defined as the company's total assets minus total liabilities. ROE shows how much profits a company generates with the money shareholders invested (or with retained earnings). |
|
Return on Assets (ROA) Return on Assets (ROA) is net income relative to total assets. The market research on Research & Development in the Physical, Engineering & Life Sciences measures how efficiently the company leverages its assets to generate profit. ROA is calculated as Net Income divided by Total Assets. |
Liquidity Ratios | Industry Average |
---|---|
Bankers and suppliers use liquidity to determine creditworthiness and identify potential threats to a company's financial viability. | |
Current Ratio Measures a firm's ability to pay its debts over the next 12 months. |
|
Quick Ratio (Acid Test) Calculates liquid assets relative to liabilities, excluding inventories. |
Efficiency Ratios - Key Performance Indicators | Industry Average |
---|---|
Measure how quickly products and services sell, and effectively collections policies are implemented. | |
Receivables Turnover Ratio If this number is low in your business when compared to the industry average in the research report, it may mean your payment terms are too lenient or that you are not doing a good enough job on collections. |
|
Average Collection Period Based on the Receivables Turnover, this estimates the collection period in days. Calculated as 365 divided by the Receivables Turnover |
|
Inventory Turnover A low turnover rate may point to overstocking, obsolescence, or deficiencies in the product line or marketing effort. |
|
Fixed-Asset Turnover Generally, higher is better, since it indicates the business has less money tied up in fixed assets for each dollar of sales revenue. |
Compensation & Salary Surveys for Employees
Compensation statistics provides an accurate assessment of industry-specific jobs and national salary averages. This information can be used to identify which positions are most common, and high, low, and average annual wages.Title | Percent of Workforce | Bottom Quartile | Average (Median) Salary | Upper Quartile |
---|---|---|---|---|
Management Occupations | 14% | Order at top of page |
||
Chief Executives | 0% | |||
General and Operations Managers | 2% | |||
Other Management Occupations | 6% | |||
Business and Financial Operations Occupations | 10% | |||
Business Operations Specialists | 8% | |||
Computer and Mathematical Occupations | 12% | |||
Computer Occupations | 11% | |||
Software Developers and Programmers | 5% | |||
Architecture and Engineering Occupations | 17% | |||
Engineers | 14% | |||
Life, Physical, and Social Science Occupations | 25% | |||
Life Scientists | 12% | |||
Medical Scientists | 7% | |||
Medical Scientists, Except Epidemiologists | 7% | |||
Life, Physical, and Social Science Technicians | 7% | |||
Office and Administrative Support Occupations | 9% |
Research & Development in the Physical, Engineering & Life Sciences Competitor Landscape & Key Companies [PREMIUM]
The most influential companies in the Research & Development in the Physical, Engineering & Life Sciences industry and adjacent industries either have large market share or are developing new business models and methods that could disrupt the status quo. We look at leading and emerging companies in the Research & Development in the Physical, Engineering & Life Sciences industry and adjacent sectors:Market Leaders: Direct Competitors Companies with the largest market share, focused in this industry |
Market leaders: Diversified Competitors Largest companies that have diversified operations in this and other industries |
Innovators: Direct Competitors Innovative, Emerging, and Disruptive Companies that may influence the future direction of the industry. |
Innovators: Diversified Competitors Innovators and Disruptors in adjacent industries that may also affect the Research & Development in the Physical, Engineering & Life Sciences industry. |
Executive Briefings
We are engaged in segments of the pharmaceutical industry that are highly competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are commercializing or pursuing the development of products that target HCV, RSV, HBV, NASH, hMPV and SARS-CoV-2 and other viral infections or liver diseases that we may target in the future. Many of our competitors have substantially greater commercial infrastructures and financial, technical and personnel resources than we have, as well as drug candidates in late-stage clinical development. We will not be able to compete successfully unless we are able to: • design and develop products that are superior to other products in the market; • attract qualified scientific, medical, regulatory, sales and marketing and commercial personnel; • obtain patent and/or other proprietary protection for our processes and product candidates; • obtain required regulatory approvals; or • collaborate with others in the development and commercialization of new products. Established competitors may invest heavily to quickly discover and develop novel compounds that could make our product candidates obsolete. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety, or some combination of these factors, to overcome competition and to be commercially successful. We expect AbbVie’s MAVYRET/MAVIRET to continue to face intense competition due to existing approved products in the HCV market. AbbVie’s HCV treatment regimens currently face competition in various world markets and subpopulations of HCV from Gilead’s Epclusa® (a fixed dose combination of sofosbuvir and velpatasvir), Vosevi® (a triple combination therapy of sofosbuvir, velpatasvir and voxilaprevir approved by the FDA in July 2017 for specified sofosbuvir -treatment failures and NS5A-inhibitor treatment failures) and Harvoni® (a fixed-dose combination of sofosbuvir and ledipasvir); and to a lesser extent - Merck’s Zepatier® (a fixed-dose combination of grazoprevir and elbasvir). Gilead launched authorized generic versions of Epclusa and Harvoni in January 2019 through a newly created subsidiary, Asegua Therapeutics, LLC, which has had an impact on the competitive landscape. Other competitive products in the form of other treatment methods or a vaccine for HCV may render AbbVie’s HCV regimens obsolete or noncompetitive. AbbVie’s regimens that contain one of our collaboration’s protease inhibitors will face competition based on their safety and effectiveness, reimbursement coverage, price, patent position, AbbVie’s marketing and sales capabilities, and other factors. If any of AbbVie’s HCV regimens face competition from generic products other than authorized generic versions by the manufacturer of the branded product (i.e. If AbbVie is not able to compete effectively against its competitors in HCV, our business will not grow and our financial condition, operations and stock price will suffer. 16 We also expect our other product candidates to face intense and increasing competition in the NASH and antiviral markets as advanced technologies and products become available. Though there is currently no approved treatment for NASH, we expect significant competition from other companies in the development of new treatments for NASH and related conditions. In February 2019, Intercept Pharmaceuticals announced positive Phase 3 trial results for OCA (brand name Ocaliva®) in NASH and submitted U.S. We are aware of several other companies with NASH programs that are significantly more advanced than ours, including companies with compounds in Phase 3 clinical trials in NASH, namely AbbVie, Galmed, Intercept, and Madrigal. In addition, a number of companies have NASH or related programs with compounds in Phase 2 clinical trials. These companies include 89bio, Afimmune, Akcea, Akero, AngioLab, AstraZeneca, BMS, Can-Fite BioPharma, Cirius, Cymabay, Eli Lilly and Company, Enyo, Galectin, Gilead, HighTide Biopharma, Immuron, Inventiva, Kowa Company, Lipocine, Medicinova, Metacrine, Mitsubishi Tanabe Pharma, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis, Novo Nordisk, NuSirt Biopharma, Pfizer, Poxel SA, PharmaKing, Sagimet Biosciences, TaiwanJ Pharmaceuticals, Terns, Theratechnologies, Viking Therapeutics, and Zydus. A significant number of other companies are conducting earlier stage clinical trials that may be applicable in NASH. There are also additional companies conducting preclinical studies in these disease areas. Similarly, HBV and RSV represent competitive therapeutic areas. Many companies are seeking to develop new HBV drugs that alone or in combination with other mechanisms could lead to a functional cure of HBV. Assembly, Gilead, GSK/Ionis, HEC, Johnson Enanta Pharmaceuticals
Government Contracts
In 2020, the federal government spent a total of $331,844,138,177 on Research & Development in the Physical, Engineering & Life Sciences. It has awarded 12589 contracts to 3386 companies, with an average value of $98,004,766 per company.Most Recent Contracts | Date | Total Award Amount |
---|

